Struthers Richard Scott 4

What Happened
Richard Scott Struthers, President & CEO and a director of Crinetics Pharmaceuticals (CRNX), sold a total of 21,981 shares in two open-market transactions on March 16, 2026. The sales were: 13,196 shares at a volume-weighted average price (VWAP) of $37.11 (proceeds ≈ $489,704) and 8,785 shares at a VWAP of $37.77 (proceeds ≈ $331,809), for combined proceeds of about $821,513. These were sales (not purchases) and were effected to satisfy tax withholding on vested Restricted Stock Units.

Key Details

• Transaction dates: March 16, 2026; Form 4 filed March 18, 2026 (timely filing).
• Prices and ranges:
  • 13,196 shares sold at VWAP $37.11; daily price range $36.42–$37.38.
  • 8,785 shares sold at VWAP $37.77; daily price range $37.42–$38.23.
• Total shares sold: 21,981; total proceeds ≈ $821,513.
• Reason/footnotes: Sales were to cover the Reporting Person’s tax withholding obligation on RSUs (granted Feb 28, 2022; Mar 1, 2023; Mar 4, 2024) and were executed by a broker under a Rule 10b5-1 trading plan.
• Shares owned after transaction: not specified in the supplied summary (see the issuer’s full Form 4 for post-transaction holdings).

Context
These sales were routine tax-withholding transactions tied to RSU vesting and executed under a pre-established 10b5-1 plan. Such transactions are common and do not, by themselves, indicate the insider’s view of the company’s prospects. Purchases generally carry more informational weight for signaling insider confidence than routine withholding sales.